Lead Product(s) : LNA043,Canakinumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNA043 is a ANGPTL3 agonist that targets damaged cartilage and modulates several pathways involved in cartilage regeneration. LNA043 resulted in regeneration of damaged cartilage in patients with femoral articular cartilage lesions in a proof of concept ...
Product Name : LNA043
Product Type : Protein
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : LNA043,Canakinumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable